Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;51(3):334-8.
doi: 10.1002/pbc.21618.

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group

Patrick J Leavey  1 , Leo Mascarenhas, Neyssa Marina, Zhengjia Chen, Mark Krailo, James Miser, Ken Brown, Nancy Tarbell, Mark L Bernstein, Linda Granowetter, Mark Gebhardt, Holcombe E Grier; Children's Oncology Group
Affiliations

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group

Patrick J Leavey et al. Pediatr Blood Cancer. 2008 Sep.

Abstract

Background: The prognosis for patients with recurrent Ewing sarcoma (EWS) is very poor with 5-year survival of 13%.

Methods: To evaluate prognostic factors for these patients we studied patients initially treated on the multi-institutional study INT0091.

Results: Two hundred sixty-two patients experienced disease recurrence. The median time to first recurrence was 1.3 years (0-7.4 years), 1.4 years (0-7.4 years) for patients with initially localized disease and 1 year (0-6 years) for patients with initially metastatic disease. Time to first recurrence from date of initial diagnosis was a predictor of post-recurrence survival (P < 0.0001). Twenty-one percent of patients, with recurrent or progressive disease >or=2 years from initial diagnosis, had an estimated 5-year survival of 30% (vs. 7% estimated 5-year survival with an earlier recurrence). No statistical difference was detected between patients whose disease recurred <1 year and between 1 and 2 years from initial diagnosis. A stepwise relative risk model and backwards stepwise regression was used to explore factors significantly associated with risk for post-recurrence death. Significant risk factors for death after recurrence included recurrence at combined local and distant sites, elevated LDH at initial diagnosis and initial recurrence less than 2 years after diagnosis. Isolated pulmonary recurrence was not predictive of survival after recurrence.

Conclusion: Patients with a longer disease control interval represent the subset of patients most likely to survive following recurrence of EWS. All patients with recurrence would benefit from collaborative trials to investigate new therapeutic options.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curve for all patients treated on INT0091 who developed recurrence as the first analytic event.
Figure 2
Figure 2
Survival curve for all patients by time to first recurrence from initial diagnosis.
See this image and copyright information in PMC

References

    1. Guerney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Gloecker Ries LA, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. Bethesda: NCI; 1999. pp. 99–110.
    1. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N.Engl.J Med. 2003;348:694–701. - PubMed
    1. Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr.Blood Cancer. 2007 - PubMed
    1. Bacci G, Mercuri M, Longhi A, et al. Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur.J Cancer. 2002;38:2243–2251. - PubMed
    1. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med.Pediatr.Oncol. 2003;40:141–147. - PubMed

Publication types